EirGenix

EirGenix Contract Manufacturing & Development (CDMO) Profile

EirGenix is Taiwan’s largest contract development and manufacturing organization (CDMO) for mammalian and microbial-derived biologics, providing full, one-stop services from pre-clinical development to commercial manufacturing. EirGenix has extensive experience with various biologics including monoclonal and bi/poly-specific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), and plasmid DNAs. EirGenix is also the only CDMO in Taiwan to have its biomanufacturing facilities approved by multiple international regulatory authorities like the USFDA, Japan PMDA, Australia TGA, and EU EMA.

CDMO Services:
Biologics Drug Substance Manufacturing (API); Drug Product Formulation (FDF); Regulatory Services; Analytical Development Sterile Vials Analytical Development; Cell Line Development; Formulation Development; ICH Stability Testing; Process Development; Protein Synthesis Antibodies; Antibody-drug conjugate (ADC); Fusion Proteins; Recombinants + other Proteins; Protein Vaccines; Plasmid DNA

Year Founded: 2012

Head Office: New Taipei City, Taiwan, Province of China

Number of Facilities: 2

Facility locations: South-East Asia

Website: Visit the EirGenix website

Linkedin: Connect on Linkedin

Current Capacity: EirGenix has a current capacity of 3 x 1,000L SUBs & 12 x 2,000 L SUBs for mammalian production and 350 L & 150 L SUFs for microbial production. In 2025 we will add an additional 1,000 L SUF for microbial.